Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis

Not Applicable

Completed

• Conditions: Systemic Sclerosis; Primary Raynaud Disease
• Interventions: Biological: soluble Ve cadherin

• Registration Number: NCT02212249
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadherin antibody in patients with systemic slerosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-04-23
• Study Start: 2014-05
• Study First Submitted QC: 2014-08-06
• Study First Posted: 2014-08-08
• Status Verified: 2016-03
• Primary Completion: 2016-03
• Study Completion: 2016-03
• Last Update Submitted: 2016-03-23
• Last Update Posted: 2016-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

• group 1: systemic sclerosis
• group 2: raynaud primary disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Systemic sclerosis	soluble Ve cadherin	patients with systemic sclerosis
primary raynaud disease	soluble Ve cadherin	patients with primary raynaud disease

Primary Outcome Measures

Name	Time	Method
Level of soluble Ve-cadherin and antibody VE-cadherin with ELISA TEST in Scleroderma group versus Primary Raynaud's Phenomenon	At 30 days average	Level of human sVE and antibody VE-cadherin in blood will be determined by ELISA test in both groups Scleroderma and Primary Raynaud's Phenomenon.; The methodology of dosage of sVE is based on the pattern:WO/2008/062314 The methodolody of the dosage of antibody VE-cadherin is based on the pattern WO/2012/136820 .; Group Scleroderma (N=60) versus Primary Raynaud's Phenomenon (N=20). Shapiro test.

Trial Locations

Locations (1)

Grenoble University Hospital; 🇫🇷 Grenoble, France